Shares of Seres Therapeutics Inc. (NASDAQ:MCRB) traded up 3.1% during trading on Monday . The stock traded as high as $34.17 and last traded at $33.76, with a volume of 158,514 shares trading hands. The stock had previously closed at $32.73.

Several analysts have recently commented on the stock. Leerink Swann restated a “buy” rating and set a $43.00 price objective on shares of Seres Therapeutics in a research report on Thursday. FBR & Co reaffirmed a “buy” rating on shares of Seres Therapeutics in a research note on Friday, July 8th. Cowen and Company reaffirmed a “buy” rating on shares of Seres Therapeutics in a research note on Monday, June 13th. Canaccord Genuity reaffirmed a “buy” rating on shares of Seres Therapeutics in a research note on Sunday, May 29th. Finally, Zacks Investment Research cut shares of Seres Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, May 18th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $43.86.

The firm’s market capitalization is $1.32 billion. The company has a 50-day moving average price of $30.69 and a 200 day moving average price of $28.15.

Seres Therapeutics (NASDAQ:MCRB) last released its quarterly earnings data on Monday, May 16th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.48) by $0.02. The firm had revenue of $2.71 million for the quarter, compared to analyst estimates of $1.25 million. Equities analysts anticipate that Seres Therapeutics Inc. will post ($1.81) earnings per share for the current fiscal year.

In related news, EVP John G. Aunins sold 18,640 shares of the business’s stock in a transaction on Monday, April 25th. The shares were sold at an average price of $31.94, for a total value of $595,361.60. Following the completion of the transaction, the executive vice president now directly owns 56,060 shares in the company, valued at approximately $1,790,556.40. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, major shareholder Ventures Fund 2007 L. Flagship sold 1,000,000 shares of the business’s stock in a transaction on Wednesday, May 25th. The shares were sold at an average price of $27.60, for a total transaction of $27,600,000.00. The disclosure for this sale can be found here.

Several institutional investors have recently bought and sold shares of MCRB. Jennison Associates LLC boosted its position in Seres Therapeutics by 1.9% in the fourth quarter. Jennison Associates LLC now owns 398,959 shares of the company’s stock valued at $13,999,000 after buying an additional 7,259 shares in the last quarter. Morgan Stanley boosted its position in Seres Therapeutics by 225.3% in the fourth quarter. Morgan Stanley now owns 33,758 shares of the company’s stock worth $1,185,000 after buying an additional 23,381 shares in the last quarter. Finally, ProShare Advisors LLC bought a new position in Seres Therapeutics during the fourth quarter worth $1,146,000.

Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a range of biological drugs, Ecobiotic microbiome therapeutics. It is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome in the human body.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.